Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). Tolerability & Disease Control Rate: Shows...
Read More Details
Finally We wish PressBee provided you with enough information of ( Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma )
Also on site :
- 3 Most Prophetic Zodiac Signs, According to Astrologers
- Police say a 16-year-old was fatally stabbed by another student at a Texas track meet
- The Latest: Business leaders warn Trump tariffs will raise prices for US consumers